Loading…

NLRP3 inflammasome in depression: A review

•The NLRP3 Inflammasome activation causes the development of different chronic diseases.•Novel drugs for the treatment of depression by inhibiting NLRP3 inflammasome activation.•Several pathways that activate the NLRP3 inflammasome in depression.•Correlation between NLRP3 and depression.•Diagnostic...

Full description

Saved in:
Bibliographic Details
Published in:International immunopharmacology 2023-04, Vol.117, p.109916-109916, Article 109916
Main Authors: Roy, Salona, Arif Ansari, Md, Choudhary, Khushboo, Singh, Sanjiv
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:•The NLRP3 Inflammasome activation causes the development of different chronic diseases.•Novel drugs for the treatment of depression by inhibiting NLRP3 inflammasome activation.•Several pathways that activate the NLRP3 inflammasome in depression.•Correlation between NLRP3 and depression.•Diagnostic marker for NLRP3 induced depression. The present article provides a detailed concept of the role of NLRP3 inflammasome in the pathophysiology of depression-like chronic diseases where inflammation and release of various cytokines plays a pivotal role in exaggerating the condition. The various pathways involved in NLRP3 activation are the main target of NLRP3 inhibitors for the therapeutic management of depression as per the recent clinical and research studies conducted so far. Further various drug inhibitors for NLRP3 available in preclinical and clinical trials have been discussed in detail. Hence, blockage of the action of NLRP3 inflammasome is crucial to anticipate the inflammatory cytokine release from the mediators that contributes to cause depression.
ISSN:1567-5769
1878-1705
DOI:10.1016/j.intimp.2023.109916